Time filter

Source Type

Li Z.H.,Nanchang University | Li Z.H.,Third Hospital of Nanchang City | Xiong J.P.,Nanchang University | Hu P.H.,Third Hospital of Nanchang City | Tu J.H.,Third Hospital of Nanchang City
European Journal of Gynaecological Oncology | Year: 2017

Background: Patients with luminal breast cancer have better prognosis and survival rates compared to patients with non-luminal breast cancers, such as basal-like and HER-2 subtypes, owing to the added benefits of adjuvant endocrine therapy. However, local relapses and distant metastasis still frequently occur. In recent years, more studies on breast cancer relapse and metastasis have focused on non-luminal breast cancers despite there being more number of cases of luminal breast cancer. Materials and Methods: In this study, the authors included 387 breast cancer patients with recurrence and metastasis who were treated in their hospital between January 2001 and June 2011, and divided them into luminal and non-luminal groups. The differences in clinical and pathological characteristics, survival rates, and prognostic features after follow-up treatment were retrospectively analyzed in the two groups. Results: The authors found there was a higher proportion of local recurrence and single bone metastasis in luminal group than in the non-luminal group. The risk of recurrence and metastasis in the luminal group two to five years and after five years post-operation continued to be stable, but the risk in the non-luminal group significantly decreased after two years. Conclusions: Luminal breast cancer patients with recurrence or/and metastasis had better prognosis after reasonable treatment. These results are of potential clinical relevance, especially for clinical prognosis monitoring and targeted therapy interventions in patients with luminal breast cancer. © 2017, S.O.G. Canada Inc. All rights reserved.


Hu G.,Beijing Hospital and Beijing Institute of Geriatrics | Liu J.,Third Hospital of Nanchang City | Zhen Y.-Z.,Hebei United University | Xu R.,Beijing Hospital and Beijing Institute of Geriatrics | And 4 more authors.
Acta Pharmacologica Sinica | Year: 2013

Aim: To investigate the protective effects of rhein lysinate (RHL), a major bioactive constituent of the rhizome of rhubarb (Rheum palmatum Linn or Rheum tanguticum Maxim), against kidney impairment in senescence-prone inbred strain 10 (SAMP10) mice. Methods: SAMP10 mice were orally administered RHL (25 or 50 mg/kg) daily until 50% of the mice died. Senescence-resistant inbred strain 1 (SAMR1) mice administered no drug were taken as control. The kidneys were harvested after animal death, and examined morphologically and with immunochemical assays. The levels of MAD, SOD and GSH-px in the kidneys were measured with a photometric method. The expression of inflammatory factors and related proteins in the kidneys was analyzed using Western blotting. Results: Treatment of SAMP10 mice with RHL had no effect on the body weight or phenotype. However, RHL significantly prolonged the median survival time of SAMP10 mice by approximately 25%, as compared to untreated SAMP10 mice. Compared SAMR1 mice, SAMP10 mice had a significantly lower level of SOD in the kidneys, but had no significant difference in the MDA or GSH-px levels. Treatment of SAMP10 mice with RHL significantly reduced the MAD level, and increased the SOD and GSH-px levels in the kidneys. Glomerulonephritis was observed in SAMP10 mice but not in SAMR1 mice. RHL decreased the incidence of glomerulonephritis, and significantly decreased the levels of TNF-α, IL-6, NF-κB, collagen types I and III in the kidneys.Conclusion:Accelerated senescence is associated with glomerulonephritis in SAMP10 mice, and RHL prolongs their median survival time by reducing the severity of glomerulonephritis. © 2013 CPS and SIMM All rights reserved.


Zhang C.,Capital Medical University | Zhen Y.-Z.,Hebei United University | Lin Y.A.-J.,Beijing Hospital | Liu J.,Third Hospital of Nanchang City | And 3 more authors.
Molecular Medicine Reports | Year: 2014

KNDC1 (kinase noncatalytic C-lobe domain containing 1), a brain-specific Ras guanine nucleotide exchange factor, controls the negative regulation of neuronal dendrite growth. However, the effect of KNDC1 on cellular senescence remains to be elucidated. The present study investigated the impact of KNDC1 knockdown on human endothelial cell senescence and the mechanisms underlying this effect. Human umbilical vein endothelial cells (HUVECs) cultured in vitro were used as a model of biological aging. Senescence-associated β-galactosidase staining was used to detect cellular senescence and flow cytometry was employed to determine cell cycle progression. Quantitative polymerase chain reaction (qPCR) and western blot analysis were utilized to investigate mRNA transcription and protein expression. In the HUVECs, a senescence-like phenotypes developed with increasing passage number in vitro, which were associated with a progressive increase in the transcription and expression of KNDC1. KNDC1 knockdown promoted cell proliferation and partially reversed cellular senescence and cell cycle arrest in the G0/G1 phase in aging HUVECs. Investigations into the mechanism underlying this effect demonstrated that KNDC1 knockdown promoted HUVEC proliferation via the extracellular signal-regulated kinase signaling pathway and delayed HUVEC senescence by inhibiting the p53-p21-p16 transduction cascade. In addition, the promotion of the capillary tube network formation and the increased expression of endothelial nitric oxide synthase revealed that the activity and function of endothelial cells were enhanced. In conclusion, KNDC1 knockdown delayed endothelial cell senescence and promoted HUVEC activity and function. These results demonstrated that KNDC1 may be a novel therapeutic target for the development of agents to extend human life.


Hu G.,Beijing Hospital and Beijing Institute of Geriatrics | Liu J.,Third Hospital of Nanchang City | Zhen Y.-Z.,Hebei United University | Wei J.,Beijing Hospital and Beijing Institute of Geriatrics | And 3 more authors.
American Journal of Chinese Medicine | Year: 2013

Reducing the expression of endothelial cell adhesion molecules (ECAMs) is known to decrease inflammation-induced vascular complications. In this study, we explored whether rhein can reduce the inflammation-induced expression of ECAMs in human umbilical vein endothelial cells (HUVECs) with or without lipopolysaccharide (LPS) stimulation. HUVECs were treated with different concentrations of rhein with or without 2.5 μg/ml LPS stimulation. Cell viability was assayed using the MTT method. Real-time PCR and Western blot analysis were used to measure the transcription and expression levels of ECAMs, including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-SELECTIN and related signaling proteins. The results indicated that rhein (0-20 μmol/L) and LPS (0-10 μg/ml) had no effect on the viability of HUVECs. LPS could promote the expression of VCAM-1, ICAM-1 and E-SELECTIN. Rhein appeared to target VCAM-1, ICAM-1 and E-SELECTIN, with the transcription and expression of all three factors being reduced by the rhein treatment (10 and 20 μmol/L). The transcription and expression of VCAM-1 were also reduced by treatment with rhein (10 and 20 μmol/L) in the presence of LPS stimulation. In conclusion, rhein treatment reduced the expression of VCAM-1 in HUVECs via a p38-dependent pathway. © 2013 World Scientific Publishing Company & Institute for Advanced Research in Asian Science and Medicine.


Liu J.,Third Hospital of Nanchang City | Hu G.,Beijing Hospital and Beijing Institute of Geriatrics | Xu R.,Beijing Hospital and Beijing Institute of Geriatrics | Qiao Y.,Jilin University | And 5 more authors.
Journal of Asian Natural Products Research | Year: 2013

The protective effect of rhein lysinate (RHL) on Alzheimer's disease (AD) was explored in senescence-accelerated mouse prone-8 (SAMP8) mice. SAMP8 mice without treatment were used as the AD-positive control, and senescence- accelerated-resistant mice were used as the AD-negative control. In this study, 4-month-old male SAMP8 mice were orally administered 25 and 50 mg/kg RHL in drinking water for 6 months. The results of brain tissue enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and Western blot were demonstrated that compared with SAMP8 group, β-amyloid1-40 and β-amyloid1-42 were reduced; the levels of tumor necrosis factor-α and interleukin 6 of brain tissues were also significantly decreased; however, the level of sirtuin 1 (SIRT1) was increased in the RHL-treated group. Compared with SAMP8 group, the ROS levels and malondialdehyde levels were decreased; however, superoxide dismutase and glutathione peroxidase levels were increased in the brain tissues of SAMP8 25 and 50 mg/kg RHL-treated groups. In conclusion, the reduction of Aβ induced by RHL was related to the increase of SIRT1 and the inhibition of the inflammatory response and oxidative stress in SAMP8 mice. It might be a promising biological therapeutic drug for AD. © 2013 Copyright Taylor and Francis Group, LLC.


Li Z.-H.,Third Hospital of Nanchang City | Li Z.-H.,Nanchang University | Lei Q.-M.,Third Hospital of Nanchang City | Xiong J.-P.,Nanchang University
Chinese Journal of Cancer Prevention and Treatment | Year: 2015

OBJECTIVE: To evaluate the correlation of p53 expression in breast cancer and clinical response to neoadjuvant chemotherapy, which provide the basis for standardized and individualized treatment. METHODS: The databases of Cochrane, PubMed, Embase, CNKI, WanFang, VIP were searched from April of 2000 to November of 2013 for collecting the case-control studies on the correlation of p53 protein expression in breast cancer and clinical response to neoadjuvant chemotherapy. According to some standard techniques, these studies were classified and the original data were collected by meta analysis and statistical treatment. RESULTS: A total of 22 studies were recruited, p53 expression was positive in 762 cases, including 478 cases good response, and p53 expression was negative in 1 094 cases, including 762 cases good response. Meta analysis showed no significant difference in clinical response between p53 positive groups and p53 negative groups [OR=0.69, 95%CI(0.44-1.09), P=0.11]. In further stratified analyses, p53 over expression was associated with good response in breast cancer patients with neoadjuvant chemotherapy after unified cutoff as ≥ 10%[OR=0.49, 95%CI(0.29-0.82), P=0.006], but this association also not existed among the studies using anthracycline-based neoadjuvant chemotherapy or paclitaxel combined chemotherapy [OR=0.65, 95%CI(0.24-1.76), P=0.40] and [OR=0.70, 95%CI(0.4-1.25), P=0.23]. CONCLUSIONS: The results of the present meta-analysis suggest it is not simple idea that p53 status is a predictive factor for response in breast cancer patients undergoing neoadjuvant chemotherapy, even for anthracycline based chemotherapy or paclitaxel combined chemotherapy. But After unified the cutoff as ≥10%, p53 over expression may be an indicator for good response in breast cancer patients with neoadjuvant chemotherapy. p53 status may suggest a role for neoadjuvant chemotherapy and also be an index for standardized and individualized treatment in breast cancer. ©, 2015, The Editorial Board of Chinese Journal of Cancer Prevention and Treatment. All right reserved.


Li Z.-H.,Third Hospital of Nanchang City | Li Z.-H.,Nanchang University | Xiong Q.-Y.,Third Hospital of Nanchang City | Tu J.-H.,Third Hospital of Nanchang City | And 6 more authors.
Medical Oncology | Year: 2013

Tau is a microtubule-associated protein and expressed in normal breast epithelial cells and breast cancer. Tau expression in breast cancer may be important for chemotherapy optimization. This study is to investigate the expression of Tau in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy. Levels of Tau protein in advanced breast cancer were detected immunohistochemically. The chemotherapeutic efficacy indexes in Tau- group, which includes the remission rate, Miller-Payne pathological reactive grade, and pathologic complete response rate, were improved compared with that in Tau+ group. There was difference in the efficacy indexes among ER+ subgroups but not among ER-patients. In addition, Tau expression was positively correlated (r = 0.32, P < 0.00). In multivariate analysis, when age, clinical stage, postoperative lymph node metastasis, ER, PR, HER2, Ki-67, TP53, or Tau status were included, postoperative lymph node metastasis and Taunegative status were identified as independent predictors of pathologic complete response. In conclusion, negative Tau protein expression may be an effective predictor for taxane-containing neoadjuvant chemotherapy, especially in ER+ subgroups. Further study on the molecular mechanism and utility of Tau for individualizing adjuvant chemotherapy is warranted. © Springer Science+Business Media New York 2013.


Hu P.-H.,Nanchang University | Gao G.-P.,Nanchang University | Yu Y.,Third Hospital of Nanchang City | Pei C.-G.,Nanchang University | And 4 more authors.
Journal of International Medical Research | Year: 2015

Objectives: To determine the typical corneal changes in pure microphthalmia using a corneal topography system and identify characteristics that may assist in early diagnosis. Methods: Patients with pure microphthalmia and healthy control subjects underwent corneal topography analysis (Orbscan IIZ® Corneal Topography System; Bausch and Lomb, Bridgewater, NJ, USA) to determine degree of corneal astigmatism (mean A), simulation of corneal astigmatism (sim A), mean keratometry (mean K), simulated keratometry (sim K), irregularities in the 3 - and 5-mm zone, and mean thickness of nine distinct corneal regions. Results: Patients with pure microphthalmia (n = 12) had significantly higher mean K, sim K, mean A, sim A, 3.0 mm irregularity and 5.0 mm irregularity, and exhibited significantly more false keratoconus than controls (n = 12). There was a significant between-group difference in the morphology of the anterior corneal surface and the central curvature of the cornea. Conclusions: Changes in corneal morphology observed in this study could be useful in borderline situations to confirm the diagnosis of pure microphthalmia. © The Author(s) 2015.


PubMed | Nanchang University and Third Hospital of Nanchang City
Type: Journal Article | Journal: The Journal of international medical research | Year: 2015

To determine the typical corneal changes in pure microphthalmia using a corneal topography system and identify characteristics that may assist in early diagnosis.Patients with pure microphthalmia and healthy control subjects underwent corneal topography analysis (Orbscan IIZ Corneal Topography System; Bausch and Lomb, Bridgewater, NJ, USA) to determine degree of corneal astigmatism (mean A), simulation of corneal astigmatism (sim A), mean keratometry (mean K), simulated keratometry (sim K), irregularities in the 3 - and 5-mm zone, and mean thickness of nine distinct corneal regions.Patients with pure microphthalmia (n = 12) had significantly higher mean K, sim K, mean A, sim A, 3.0 mm irregularity and 5.0 mm irregularity, and exhibited significantly more false keratoconus than controls (n = 12). There was a significant between-group difference in the morphology of the anterior corneal surface and the central curvature of the cornea.Changes in corneal morphology observed in this study could be useful in borderline situations to confirm the diagnosis of pure microphthalmia.

Loading Third Hospital of Nanchang City collaborators
Loading Third Hospital of Nanchang City collaborators